Sea Change In Medtech As Industry Leans To US For New Innovation

Reimbursement has become a major obstacle to innovation

An expansive study shows the US has emerged over Europe as the preferred launch site for new medical technology because the Food and Drug Administration responds more effectively to innovation than do European regulators.

American and EU flags
• Source: Alamy

As medical devices and diagnostics become ever more sophisticated and complex, companies are opting to launch new products in the US rather than Europe, according to an expansive study from UCLA Biodesign, the healthcare technology innovation hub at the University of California Los Angeles, and global management consulting firm Boston Consulting Group (BCG).

The March 2022 study, “Interstates and Autobahns: Global Medtech Innovation and Regulation in the Digital Age,” says this pattern...

More from Regulation

More from Policy & Regulation